Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin With Liposomal-Annamycin.

Abstract

Nine patients with metastatic breast carcinoma refractory to doxorubicin were entered in a Phase II study of liposomal-annamycin, a new anthracycline antibiotic which has shown ability to circumvent multidrug resistance. A total of 14 doses of liposomal- annamycin were given at three different dose levels. Toxicity was mild and limited to granulocytopenia in less than 50% of patients. No antitumor responses were seen.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 1998
Accession Number
ADA361863

Entities

People

  • Roman Perez-soler

Organizations

  • The University of Texas MD Anderson Cancer Center

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Biomedical Research
  • Breast Cancer
  • Cancer
  • Carcinoma
  • Diseases And Disorders
  • Federal Law
  • Information Operations
  • Materials
  • Molecules
  • Neoplasms
  • Recombinant Dna
  • Therapy
  • Toxicity

Fields of Study

  • Medicine

Readers

  • Oncology (Cancer Research).